tert-butyl 4-(4-methoxyphenoxy)piperidine-1-carboxylate | 333954-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(4-methoxyphenoxy)piperidine-1-carboxylate
• 英文别名: 1,1-Dimethylethyl 4-(4-methoxyphenoxy)-1-piperidinecarboxylate
• CAS: 333954-84-0
• 化学式: C₁₇H₂₅NO₄
• mdl: MFCD16620887
• 分子量: 307.39
• InChiKey: AOLJETPMFDFEDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.588
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-methoxyphenoxy)piperidine-1-carboxylate 在 盐酸 、 三溴化硼 作用下， 生成 4-(4-piperidyloxy)phenol
  参考文献：
  名称：

  PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF

  摘要：

  Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.

  公开号：

  US20240285614A1
• 作为产物：
  描述：

  4-甲氧基苯酚 、 N-Boc-4-碘哌啶 在 2,2'-联吡啶 、 copper(l) iodide 、 2,4,5,6-四(9H-咔唑-9-基)异酞腈 、 diphenyliodonium hexafluorophosphate 、 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 以54 %的产率得到tert-butyl 4-(4-methoxyphenoxy)piperidine-1-carboxylate
  参考文献：
  名称：

  芳基自由基介导的卤素原子转移 (XAT) 和铜催化的合并用于烷基碘的模块化交叉偶联型功能化

  摘要：

  在这里，我们报告了一种工具箱策略，用于将未活化的仲烷基碘与各种基于 N、O 和 C 的亲核试剂交叉偶联。该策略利用光氧化还原产生的苯基自由基介导卤素原子转移 (XAT) 并将烷基碘转化为相应自由基的能力。这些物质参与由铜介导的第二个催化循环，从而能够与各种亲核试剂形成 C-N/O/C 键。

  DOI：

  10.1021/acscatal.3c00571

文献信息

• [EN] SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION<br/>[FR] AMINOQUINOLONES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE DGKALPHA POUR ACTIVATION IMMUNITAIRE
  申请人：BAYER AG

  公开号：WO2021105115A1

  公开（公告）日：2021-06-03

  The present invention covers aminoquinolone compounds of general formula (I) : in which R1, R2, R3, R4, R5, R6, R7, R8, X and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式(I)的氨基喹啉化合物：其中R1、R2、R3、R4、R5、R6、R7、R8、X和n如此处所定义，制备所述化合物的方法，制备所述化合物有用的中间体化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗和/或预防疾病的药物组合物，特别是对二酰基甘油激酶α调节性疾病的治疗，作为单一药剂或与其他活性成分组合使用。
• Bicyclic Heterocylic Derivatives and Methods of Use
  申请人：De Lera Ruiz Manuel

  公开号：US20110130385A1

  公开（公告）日：2011-06-02

  The present invention relates to novel bicyclic heterocycle derivatives, pharmaceutical compositions comprising the bicyclic heterocycle derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. R 1 is: I, Ia, Ib ou Ic. R 2 is alkyl, alkenyl, aryl, cycloalkyl. heterocycloalkyl or heteroaryl, any of which can be optionally substituted with R 3 ; Y is —C(O)—, —S—, —S(O)—, —S(O) 2 —, —CH 2 — or —O—, such that if Y is —O— or —S—, then M is other than N and R 1 is (Ib);
• The Merger of Aryl Radical-Mediated Halogen-Atom Transfer (XAT) and Copper Catalysis for the Modular Cross-Coupling-Type Functionalization of Alkyl Iodides
  作者：Lewis Caiger、Huaibo Zhao、Timothée Constantin、James J. Douglas、Daniele Leonori

  DOI：10.1021/acscatal.3c00571

  日期：——

  cross-couple unactivated secondary alkyl iodides with various N-, O-, and C-based nucleophiles. This strategy harnesses the ability of photoredox-generated phenyl radicals to mediate halogen-atom transfer (XAT) and convert alkyl iodides into the corresponding radicals. These species engage in a second catalytic cycle, mediated by copper, which enables C–N/O/C bond formation with the various nucleophiles

  在这里，我们报告了一种工具箱策略，用于将未活化的仲烷基碘与各种基于 N、O 和 C 的亲核试剂交叉偶联。该策略利用光氧化还原产生的苯基自由基介导卤素原子转移 (XAT) 并将烷基碘转化为相应自由基的能力。这些物质参与由铜介导的第二个催化循环，从而能够与各种亲核试剂形成 C-N/O/C 键。
• PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF
  申请人：Boundless Bio, Inc.

  公开号：US20240285614A1

  公开（公告）日：2024-08-29

  Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.